InvestSMART

Nyrada Inc (ASX:NYR)

ALERT: Price-sensitive ASX Announcement for NYR
Current share price for NYR : $0.740 0.2 (37.04%)+
Announcement
Release
27 Jul 2026 8:44AM
Price at Release
$0.540
Full Release
download
Summary
Nyrada Inc, a clinical-stage biotechnology company, released its Quarterly Activities Report and Appendix 4C for the period ending 30 June 2026. The company is advancing its Xolatryp® program, with the commencement of a Phase IIa clinical trial aimed at assessing safety and efficacy in reducing heart damage in myocardial infarction patients. Financially, Nyrada maintains a solid cash position of AU$8.39 million as of 30 June 2026, supported by a AU$2.46 million R&D tax rebate and AU$0.83 million from option exercises. The company is also progressing with patent allowances in the US and is preparing an investigational new drug application for the US FDA. Xolatryp has shown promising results in preclinical oncology and cardioprotection studies.
Key Points
  • Nyrada commenced Phase IIa clinical trial for Xolatryp®.
  • Cash balance: AU$8.39 million as of 30 June 2026.
  • Received AU$2.46 million R&D tax rebate.
  • Proceeds of AU$0.83 million from option exercises.
  • US patent allowance for Xolatryp®.
  • Preparing IND application for US FDA.
  • Xolatryp® showed efficacy in preclinical oncology studies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.